Zacks Investment Research lowered shares of Aemetis Inc. (NASDAQ:AMTX) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Aemetis, Inc. is an advanced fuels and renewable chemicals company. It produces renewable chemicals and fuels using patented microbes and processes. Aemetis owns and operates an ethanol animal feed plant in California to produce D5 Advanced Biofuels using the sorghum/biogas/CHP pathway. The Company also built, owns, and operates a renewable chemicals and advanced fuels production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia. Aemetis, Inc. is headquartered in Cupertino, California. “

Separately, FBR & Co began coverage on shares of Aemetis in a research report on Monday, July 25th. They set a market perform rating and a $2.50 price objective for the company.

Shares of Aemetis (NASDAQ:AMTX) opened at 1.29 on Wednesday. Aemetis has a 1-year low of $1.01 and a 1-year high of $3.05. The stock’s market capitalization is $25.62 million. The stock’s 50 day moving average is $1.36 and its 200 day moving average is $2.02.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.01. The firm had revenue of $33.10 million for the quarter, compared to analysts’ expectations of $38.10 million. On average, equities analysts forecast that Aemetis will post ($1.04) EPS for the current year.

About Aemetis

Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.

5 Day Chart for NASDAQ:AMTX

Get a free copy of the Zacks research report on Aemetis (AMTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aemetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc. and related companies with's FREE daily email newsletter.